| | Characteristic | Non-high-dose group () | High-dose group () | -value |
| | Age (years) | | | 0.558 | | Female gender, (%) | 105 (70.0) | 44 (62.9) | 0.291 | | Creatinine (mg/dL) | | | 0.018* | | Hb (g/L) | | | 0.438 | | Platelet (×109/L) | | | 0.592 | | Use of NSAIDs, (%) | 8 (5.3) | 6 (8.6) | 0.359 | | Use of aspirin, (%) | 23 (15.3) | 9 (12.9) | 0.628 | | Use of clopidogrel, (%) | 15 (10.0) | 8 (11.4) | 0.747 | | Use of warfarin, (%) | 5 (3.3) | 5 (7.1) | 0.206 | | Coexisting illness, (%) | | | | | CKD III, IV/V | 47/17 (31.3/11.3) | 23/12 (32.9/17.1) | 0.422 | | COPD | 8 (5.3) | 3 (4.3) | 0.740 | | CAD | 21 (14.0) | 16 (22.6) | 0.102 | | DM | 38 (25.3) | 28 (40.0) | 0.027* | | CVA | 18 (12.0) | 16 (22.9) | 0.038* | | Liver cirrhosis | 26 (17.3) | 13 (18.6) | 0.321 | | Forrest classification Ia/Ib/IIa/IIb/IIc/III | 11/86/12/35/5/1 | 3/45/7/15/0/0 | 0.524 | | Shock on admission | 69 (46.0) | 43 (61.4) | 0.033* | | Rockall score | | | 0.106 | | Time to endoscope (hours) | | | 0.107 | | Hemostasis methods A/B/C/D/E/F | 11/86/12/35/5/1 | 3/45/7/15/0/0 | | | PRBC BT (mL) | | | 0.196 | | Multiple ulcers, (%) | 50 (38.7) | 26 (37.1) | 0.580 | | Rebleeding, (%) | 24 (16.0) | 19 (27.1) | 0.052 | | Surgery, (%) | 1 (0.6) | 1 (1.4) | 0.579 | | Hospital stay (days) | | | 0.343 | | Mortality, (%) | 9 (6.0) | 8 (11.4) | 0.207 | | Bleeding related/other causes | 3/6 | 1/7 | |
|
|
Hb: hemoglobin, NSAID: nonsteroidal anti-inflammatory drug, CKD: chronic kidney disease, PPI: proton-pump inhibitor, DM: diabetes mellitus type 2, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CVA: cerebrovascular accident, BT: blood transfusion, PPI: proton pump inhibitor, Hemostasis methods A/B/C/D/E/F: Bosmin plus APC/heat probe=A, APC/heat probe=B, Hemoclip=C, Bosmin plus hemoclip=D, APC/heat probe plus hemoclip=E, APC plus hemoclip plus Bosmin=F, APC: argon plasma coagulation. *.
|